Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for B-cell NHL continues to evolve rapidly, especially for DLBCL, as existing drug labels are expanded and new therapies are added to the armamentarium. New NHL market entrants include CAR T-cell therapies Tecartus (Gilead / Kite Pharma) and Breyanzi (Bristol Myers Squibb), the XPO1 inhibitor Xpovio (Karyopharm), the anti-CD19 antibody Monjuvi (MorphoSys / Incyte), the anti-CD79b antibody-drug conjugate Polivy (Roche / Genentech), the BTK inhibitor Brukinsa (BeiGene), and the PI3K inhibitor Ukoniq (TG Therapeutics). In addition, 2020 witnessed the approval of the first-in-class biomarker-driven therapy, the EZH2 inhibitor Tazverik (Epizyme), for follicular lymphoma. These novel therapies will command high prices, but their commercial success will also be determined by how well they are adopted into clinical practice.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States.
Primary research: Survey of 101 U.S. hematologist-oncologists.
Key Drugs Covered:
Aliqopa, Arzerra, Breyanzi, Brukinsa, Calquence, Copiktra, Gazyva, Imbruvica, Kymriah, Monjuvi, Polivy, Revlimid, Rituxan / Rituxan Hycela, Tazverik, Tecartus, Ukoniq, Velcade, Venclexta, Xpovio, Yescarta, Zydelig
Key Subtypes Covered: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).